Biotech RadarJobs updated

COMPANY

Immunovant

immunovant.com ↗ · Southeast

Clinical Phase 3

Profile checked Oct 10, 2026

Keywords: Chronic Inflammatory Demyelinating Polyneuropathy Graves' Disease Thyroid Eye Disease Generalized Myasthenia Gravis Primary Sjögren's Syndrome Subacute Cutaneous Lupus Erythematosus Chronic Cutaneous Lupus Erythematosus Graves Disease Rheumatoid Arthritis Myasthenia Gravis Graves' Ophthalmopathy Warm Autoimmune Hemolytic Anemia IMVT-1402 Batoclimab RVT-1401 Imeroprubart IMVT-1401 (batoclimab)

$1.0BRaised (2 yrs)19Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD) source ↗
  2. Raise Private placement: $550M (total, as published), announced Dec 11, 2025. Source: company release on GlobeNewswire. source ↗
  3. Trial start Phase 2: An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) source ↗
  4. Trial start Phase 2: Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease Activity source ↗
  5. Trial start Phase 2: A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease source ↗
  6. Trial start Phase 3: Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis source ↗
  7. Trial start Phase 2: Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) source ↗
  8. Trial start Phase 2: A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) source ↗
  9. Raise Private placement: $450M (total, as published), announced Jan 13, 2025. Source: SEC filing. source ↗
  10. Trial start Phase 2: A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis source ↗
  11. Trial start Phase 2: A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease source ↗
  12. Trial start Phase 2: A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' Disease source ↗
  13. Trial start Phase 3: Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease source ↗
  14. Trial start Phase 2: To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP source ↗
  15. Trial start Phase 3: Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease source ↗
  16. Trial start Phase 3: Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease source ↗
  17. Trial start 3: Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis source ↗
  18. Trial start Phase 2: To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA). source ↗
  19. Trial start Phase 2: ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO ) source ↗
  20. Trial start Phase 2: A Study of RVT-1401 in Myasthenia Gravis (MG) Patients source ↗
  21. Trial start Phase 2: Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO) source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $1.0B. Last 2 years.

Clinical trials (lead sponsor) 19

RecordTitlePhaseStatusStartPrimary completion
NCT07032662Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Phase 2RecruitingMar 18, 20252028-08 (estimated)
NCT07286006A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD)Phase 2Enrolling by invitationJan 26, 20262030-03 (estimated)
NCT05403541Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis3TerminatedJun 27, 2022Jan 10, 2025 (actual)
NCT06979531Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease With Moderate to Severe Systemic Disease ActivityPhase 2Active, not recruitingJun 30, 20252028-07 (estimated)
NCT06980805A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)Phase 2Active, not recruitingFeb 19, 20252026-10 (estimated)
NCT06727604A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' DiseasePhase 2RecruitingDec 17, 20242028-06 (estimated)
NCT07018323A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' DiseasePhase 2RecruitingJun 19, 20252027-05 (estimated)
NCT05907668A Proof-of-Concept Study to Assess Batoclimab in Participants With Graves' DiseasePhase 2CompletedMay 15, 2023Jul 25, 2025 (actual)
NCT07188844An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)Phase 2TerminatedAug 28, 2025Jul 16, 2026 (actual)
NCT05581199To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDPPhase 2TerminatedDec 15, 2022Jul 20, 2026 (actual)
NCT07039916Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia GravisPhase 3RecruitingMay 27, 20252027-12 (estimated)
NCT05517447Extension Study to Assess Batoclimab in Participants With Thyroid Eye DiseasePhase 3TerminatedNov 6, 2022Apr 2, 2026 (actual)
NCT06754462A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid ArthritisPhase 2Active, not recruitingJan 10, 20252027-09 (estimated)
NCT05524571Study to Assess Batoclimab in Participants With Active Thyroid Eye DiseasePhase 3CompletedJan 5, 2023Feb 3, 2026 (actual)
NCT05517421Study to Assess Batoclimab in Participants With Active Thyroid Eye DiseasePhase 3CompletedNov 23, 2022Nov 2, 2025 (actual)
NCT03863080A Study of RVT-1401 in Myasthenia Gravis (MG) PatientsPhase 2CompletedMay 21, 2019Oct 7, 2020 (actual)
NCT03938545ASCEND GO-2: Study of RVT-1401 for the Treatment of Participants With Active, Moderate to Severe Graves' Ophthalmopathy ( GO )Phase 2TerminatedJul 23, 2019Feb 2, 2021 (actual)
NCT04253236To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAIHA).Phase 2TerminatedAug 11, 2020Apr 1, 2021 (actual)
NCT03922321Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)Phase 2CompletedApr 22, 2019Feb 29, 2020 (actual)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback